Tumor-Mediated Immunosubversion: Role of Dietary Essential Fatty Acid

  • O. J. Plescia
  • J. Brown
  • D. Lombardi
  • L. Lenti
  • S. Racis
  • G. M. Pontieri
Part of the Prostaglandins, Leukotrienes, and Cancer book series (PLAC, volume 6)

Abstract

It is said that “we are what we eat”. That, we would all agree, applies to our outward physical appearance - our stature and weight. We would also agree that our diet must include certain essential nutrients for our body to function normally. Now we are being told that nutrition may also be a critical factor in promoting or reducing our risk for certain diseases. On this point, agreement is not general.

Keywords

Aspirin Adenosine Sarcoma Prostaglandin Indomethacin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Plescia, O.J., Smith, A. and Grinwich, K. (1975) Subversion of the immune system by tumor cells and the role of prostaglandins. Proc. Natl. Acad. Sci. U.S.A. 72:1848–1852.PubMedCrossRefGoogle Scholar
  2. 2.
    Plescia, O.J., Smith, A., Grinwich, K. and Feit, C. (1975) The problem of cancer immunotherapy in perspective. In: “Fundamental Aspects of Neoplasia”. Gottlieb, A., Plescia, O.J. and Bishop, D. (eds.), Academic Press, New York, pp. 139–151.Google Scholar
  3. 3.
    Bennett, A., DelTacca, M., Stamford, I.F., et al. (1977) Prostaglandins from tumors of human large bowel. Brit. J. Cancer 35:881.PubMedCrossRefGoogle Scholar
  4. 4.
    Rolland, P.H., Martin, P.M., Jacquemier, J., et al. (1980) Prostaglandins in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 64:1061.PubMedGoogle Scholar
  5. 5.
    Tashjian, A., Jr., Voelkel, E., Levine, L. and Goldhaber, P. (1972) Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E2. J. Exp. Med. 136:1329.PubMedCrossRefGoogle Scholar
  6. 6.
    Pelus, L.M. and Strausser, H.R. (1977) Prostaglandins and the immune response. Life Sci. 20:903.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldyne, M.E. and Stobo, J.D. (1981) Immunoregulatory role of prostaglandins and related lipids. CRC Critical Reviews in Immunology, 2:189.Google Scholar
  8. 8.
    Goodwin, J. and Webb, D. (1980) Regulation of the immune response by prostaglandins. Clin. Immunol. Immunopathol. 15:106–122.CrossRefGoogle Scholar
  9. 9.
    Kunkel, S.L. and Chensue, S.W. (1984) Prostaglandins and the immune response. Adv. Inflamm. Res. 7:93–109.Google Scholar
  10. 10.
    Gemsa, D. (1981) Stimulation of prostaglandin E release from macrophages and possible role in the immune response. Lymphokines Vol. II. (4), Pick, E. (ed.), Academic Press, New York, pp. 335–375.Google Scholar
  11. 11.
    Goodwin, J.S. (1980) Prostaglandin regulation of the immune response. [Letter] Cell. Immunol. 52(1):106–122.CrossRefGoogle Scholar
  12. 12.
    Plescia, O.J., Pontieri, G.M., Brown, J., Racis, S., Ippoliti, F., Bellelli, L., Sezzi, M.L. and Lipari, M. (1984) Amplification by macrophages of prostaglandin-mediated immunosuppression in mice bearing syngeneic tumors. Prost. Leuko. & Med. 16:205–223.CrossRefGoogle Scholar
  13. 13.
    Levine, L. (1982) Stimulation of cellular prostaglandin production by phorbolesters and growth factors and inhibition by cancer chemopreventive agents. In: “Prostaglandins and Cancer: First Internatinal Conference”. Powles, T.J., Bockman, R.S., Honn, K.V. and Ramwell, P., (eds.), Alan R. Liss, Inc., New York, p. 189.Google Scholar
  14. 14.
    Samuelsson, B., Bargeat, P., Hammerstrom, S., et al. (1980) Leukotrienes: A new group of biologically active compounds. In: “Advances in Prostaglandin and Thomboxane Research”. Samuelsson, B., Ramwell, P. and Paoletti, R. (eds.), Raven Press, New York, pp. 1–18.Google Scholar
  15. 15.
    Salomon, J.A. and Flower, R.J. (1982) In: “Methods in Enzymology”. W. Lands and W. Smith (eds.), Academic Press, New York, Vol. 86, p. 47.Google Scholar
  16. 16.
    Kondo, M., Koshira, Y., Kawamura, M. and Mureta, S. (1983) Biochem. J. 212:219–222.PubMedGoogle Scholar
  17. 17.
    Demers, I.M. (1984) The effects of prostaglandins. Diagnostic Medicine, pp. 37–45.Google Scholar
  18. 18.
    Racis, S.P. (1986) Prostaglandins as Physiological Immunoregulators. Ph.D. Thesis, Rutgers, The State University and The University of Medicine and Dentistry of New Jersey.Google Scholar
  19. 19.
    Webb, D.R., Rogers, T.J. and Nowowiejski, I. (1980) Endogenous prostaglandin synthesis and the control of lymphocyte function. Proc. Natl. Acad. Sci. U.S.A. 332:262–270.Google Scholar
  20. 20.
    Goodwin, J.S., Selinger, D.S., Messner, R.P. and Reed, W.P. (1978) Effect of indomethacin in vivo on humoral and cellular immunity in humans. Infect. Immun. 19:430.PubMedGoogle Scholar
  21. 21.
    Loose, L. and DiLuzio, N. (1973) Effect of prostaglandin E1 on cellular and humoral immune responses. J.R.E.S. 13:70.Google Scholar
  22. 22.
    Webb, D.R. and Nowowiejski, I. (1977) The role of prostaglandins in the control of the primary 19S immune response to SRBC. Cell Immunol. 33:1.PubMedCrossRefGoogle Scholar
  23. 23.
    Webb, D. and Osheroff, P. (1976) Antigen stimulation of prostaglandin synthesis and control of the immune responses. Proc. Natl. Acad. Sci. U.S.A. 73:1300.PubMedCrossRefGoogle Scholar
  24. 24.
    Herscowitz, H.B. and Stylos, W.A. (1975) Prostaglandin induced enhancement of the in vitro anamnestic response. Prost. 10:1848.Google Scholar
  25. 25.
    Hokama, Y., Matsuo, M., Lam, M. et al. (1980) Regulatory role of prostaglandins in the primary and secondary immune response to SRBC in mice. In: “Advances in Prostaglandin and Thromboxane Research”. Samuelsson, B., Ramwell, P. and Paoletti, R. (eds.), Raven Press, New York, pp. 1669–1674.Google Scholar
  26. 26.
    Rogers, T.J., Campell, L., Calhoun, K., Nowowiejski, I. and Webb, D.R. (1982) Suppression of B cell and T cell responses by the prostaglandin induced T cell derived suppressor (PITS). Cell. Immunol. 66:269.PubMedCrossRefGoogle Scholar
  27. 27.
    Zimecki, M. and Webb, D.R. (1976) The regulation of the immune response to T-independent antigens by prostaglandins and B cells. J. Immunol. 117:2158–2164.PubMedGoogle Scholar
  28. 28.
    Droller, M., Schneider, M. and Perlman, P. (1978) A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell. Immunol. 39:166.Google Scholar
  29. 29.
    Leung, K. and Mihich, E. (1980) Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 288:597.PubMedCrossRefGoogle Scholar
  30. 30.
    Brunda, M., Herberman, R. and Holden, H. (1980) Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol. 124:2682.PubMedGoogle Scholar
  31. 31.
    Bray, M.A., Gordon, D. and Morley, J. (1974) Role of prostaglandins in reactions of cellular immunity. Int. J. Pharmacol. 52:4530.Google Scholar
  32. 32.
    Plescia, O.J., Yamamoto, T. and Shimamura, T. (1975) Cyclic AMP and immune responses: Changes in the splenic level of cyclic AMP during the response of mice to antigen. Proc. Natl. Acad. Sci. U.S.A. 72:888–891.PubMedCrossRefGoogle Scholar
  33. 33.
    Braun, W. (1974) Regulatory factors in the immune response: Analysis and perspective. In: “Cyclic AMP, Cell Growth, and the Immune Response”. Braun, W., Lichtenstein, L.M. and Parker, C.W. (eds.), Springer-Verlag, New York, pp. 4–23.Google Scholar
  34. 34.
    Skelly, R., Steinberg, A.D. and Plescia, O.J. (1978) Regulation of antigen-induced changes in cyclic nucleotide levels in NZB/W F1 mice. Cell. Immunol. 36:282–293.CrossRefGoogle Scholar
  35. 35.
    Bourne, H.R., Lichtenstein, L.M., Melmon, K.L., Henney, C.S., Weinstein, Y. and Shearer, G.M. (1974) Modulation of inflammation and immunity by cyclic AMP. Science 184:19–28.PubMedCrossRefGoogle Scholar
  36. 36.
    Goodwin, J.S., Kaszubowski, P.A. and Williams, R.C., Jr. (1979) Cyclic adenosine monophosphate response to prostaglandin E2 on subpopulations of human lymphocytes. J. Exp. Med. 150(5): 1260–1264.PubMedCrossRefGoogle Scholar
  37. 37.
    Watson, J., Epstein, R. and Cohn, M. (1973) Cyclic nucleotides as intracellular mediators of the expression of antigen-sensitive cells. Nature 246:405.PubMedCrossRefGoogle Scholar
  38. 38.
    Parker, C.S., Sullivan, T.J. and Wedner, H.J. (1974) Cyclic AMP and the immune response. In: “Advances in Cyclic Nucleotide Research”. Robeson, G.A. and Greengard, P. (eds.), Raven Press, New York, Vol. IV, p. 1.Google Scholar
  39. 39.
    Hoffeld, J.T., Metzger, Z. and Oppenheim, J.J. (1981) In: “Lymphokines”, Vol. II. Pick, E. (ed.), Academic Press, New York, pp. 469–482.Google Scholar
  40. 40.
    Bray, M.A., Gordon, D. and Morley, J. (1976) Regulation of lymphokine secretion by prostaglandins. Agents Action 6:71.CrossRefGoogle Scholar
  41. 41.
    Dawson, W. (1982) The role of arachidonic acid products in macrophage function. In: “Prostaglandins and Related Lipids”, Vol. II. Powles, T.J., Bockman, R.S., Honn, K.V. and Ramwell, P. (eds.), Alan R. Liss, Inc., New York, pp. 609–617.Google Scholar
  42. 42.
    Humes, J.L., Bonney, R.J., Pelus, L., et al. (1977) Macrophage synthesis and release prostaglandins in response to inflammatory stimuli. Nature 269:149–151.PubMedCrossRefGoogle Scholar
  43. 43.
    Kurland, J.L. and Bockman, R. (1978) Prostaglandin E production by human monocytes and mouse peritoneal macrophages. J. Exp. Med. 147:952.PubMedCrossRefGoogle Scholar
  44. 44.
    Pelus, L.M., Bockman, R.S. (1979) Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J. Immunol. 123:2118–2122.PubMedGoogle Scholar
  45. 45.
    Salmon, S.E. (1982) Interrelationship of endogenous macrophages, prostaglandin synthesis and tumor cell clonogenicity in human tumor biopsies. In: “Prostaglandins and Related Lipids”, Vol. II. Powles, T.J., Bockman, R.S., Honn, K.V. and Ramwell, P. (eds.), Alan R. Liss, Inc., New York, pp. 633–649.Google Scholar
  46. 46.
    Stenson, W.F. and Parker, C.W. (1980) Editorial: Prostaglandins, Macrophages, and Immunity. J. Immunol. 125:1.PubMedGoogle Scholar
  47. 47.
    Goldyne, M. and Stobo, J. (1980) Prostaglandin E2 as a modulator of macrophage-T lymphocyte interaction. J. Invest. Dermat. 74:297.CrossRefGoogle Scholar
  48. 48.
    Plescia, O.J., Grinwich, K. and Plescia, A.M. (1976) Subversive activity of syngeneic tumor cells as an escape mechanism from immune surveillance and the role of prostaglandins. Ann. N.Y. Acad. Sci. 276:455.PubMedCrossRefGoogle Scholar
  49. 49.
    Bockman R.S. (1980) Stage-dependent reduction in T colony formation in Hodgkin’s disease. J. Clin. Invest. 66:528.CrossRefGoogle Scholar
  50. 50.
    Goodwin, J.S., Messner, R.P., Bankhurst, A.D., Peake, G.T., Saiki, J.H. and Williams, R.G., Jr. (1977) Prostaglandin producing suppressor cells in Hodgkin’s disease. N. Engl. J. Med. 297:-963–968.PubMedCrossRefGoogle Scholar
  51. 51.
    Fischer, R.I.U. and Bostwick-Burton, H. (1982) Depressed T cell AH3 proliferative responses in Hodgkins disease. J. Immunol. 129:1770.Google Scholar
  52. 52.
    Bockman, R.S. (1982) Prostaglandins, T Lymphocyte precursors and cancer. In: “Prostaglandins and Related Lipids”. Powles, T.J., Bockman, R.S., Honn, K.V. and Ramwell, P. (eds.), Alan R. Liss, New York, pp. 415–423.Google Scholar
  53. 53.
    Brown, J.W. (1986). Tumor-mediated Immunosuppression and neoplasia, Ph.D. Thesis, Rutgers - The State Unviersity, New Brunswick, NJ.Google Scholar
  54. 54.
    Grinwich, K. and Plescia, O.J. (1977) Tumor-mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis. Prostaglandins 14:1175–1181.PubMedCrossRefGoogle Scholar
  55. 55.
    Pelus, L.M., Strausser, H.R. (1976) Indomethacin enhancement of spleen-cell responsiveness to mitogen stimulation in tumorous mice. Int. J. Cancer 18(5): 653–660.PubMedCrossRefGoogle Scholar
  56. 56.
    Kollmorgen, G.M., Langley, R.E., Kasanke, S.O., et al. (1982). In: “First International Conference on the Modulation and Mediation of Cancer by Vitamins”. Meyskins and Prasad (eds.), Karger Press.Google Scholar
  57. 57.
    Committee on Diet, Nutrition and Cancer, National Academy of Sciences (1982). Diet, Nutrition and Cancer, National Academy Press, Washington, D.C.Google Scholar
  58. 58.
    Berenblum, I. and Shubik, P. (1947) A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse skin. Br. J. Cancer 1:373–391.Google Scholar
  59. 59.
    Boutwell, R.K. (1974) The function and mechanism of promoters of carcinogenesis. CRC Crit. Rev. Toxicol. 2:419–466.PubMedCrossRefGoogle Scholar
  60. 60.
    Hennings, H., Shores, R., Warik, M., et al. (1983) Malignant conversion of mouse skin tumor promoters is increased by tumor-initiators and unaffected by promoters. Nature 304:67–69.PubMedCrossRefGoogle Scholar
  61. 61.
    Verma, A.K., Ashendel, C.L. and Boutwell, R.K. (1980) Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins and tumor promotion caused by TPA. Cancer Res. 40:308–315.PubMedGoogle Scholar
  62. 62.
    Kersey, J.N., Spector, B.D. and Good, R.A. (1973) Immunodeficiency and cancer. Adv. Cancer Res. 18:211.PubMedCrossRefGoogle Scholar
  63. 63.
    Lahane, J.E. and Lane, M. (1974) Immunocompetence in advanced cancer patients prior to chemotherapy. Oncology 30:458.CrossRefGoogle Scholar
  64. 64.
    Hersh, E.M., Gutterman, J.U., Movliget, G.M., et al. (1976) Immunocompetence, immunodeficiency and prognosis in cancer. Ann. N.Y. Acad. Sci. 276:386–406.PubMedCrossRefGoogle Scholar
  65. 65.
    Hiel, V., Horokova, Z., Shaff, R.E., et al. (1976) Alteration of tumor growth by aspirin and indomethacin: Studies with two transplanted tumors in mice. Eur. J. Phrmacol. 37:367.CrossRefGoogle Scholar
  66. 66.
    Pollard, M. and Lucker, P.H. (1981) Treatment of chemically induced intestinal cancers with indomethacin. Proc. Natl. Acad. Sci. U.S.A. 167:161.Google Scholar
  67. 67.
    Bennett, A. (1979) Prostaglandins and cancer. In: “Practical Applications of Prostaglandins and Their Synthesis Inhibitors”. Karim, S. (ed.), University Park Press, Baltimore, pp. 149–189.Google Scholar
  68. 68.
    Plescia, O.J., Grinwich, K., Sheridan, J. and Plescia, A.M. (1978) Subversion of the immune system by tumors as a mechanism of their escape from immune rejection. Prog. Biochem. Pharmacol. 14:123–138.PubMedGoogle Scholar
  69. 69.
    Strausser, H. and Humes, J. (1975) Prostaglandin synthesis inhibition: Effect on bone changes and sarcoma tumor induction in Balb/mice. Int. J. Cancer 15:724.PubMedCrossRefGoogle Scholar
  70. 70.
    Trevisani, A., Ferretti, E., Capuzzo, A. and Tomasi, V. (1980) Elevated levels of PGE2 in Yoshida hepatoma and the inhibition of tumor growth by nonsteroidal anti-inflammatory drugs. Br. J. Cancer 41:341–347.PubMedCrossRefGoogle Scholar
  71. 71.
    Lynch, M.R. and Salomon, J. (1979) Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J. Natl. Cancer Inst. 62:117.PubMedGoogle Scholar
  72. 72.
    Goodwin, J.S. (1980) Prostaglandin synthesis inhibitors as immunoadjuvants in the treatment of cancer. J. Immunopharacol. 2:397.CrossRefGoogle Scholar
  73. 73.
    Plescia, O.J. (1982) Does prostaglandin synthesis effect in vivo tumor growth by altering tumor/host balance? In: “Prostaglandins and Cancer: First International Conference”. Powles, T.J., Bakman, R.S., Honn, K.V. and Ramwell, P. (eds.), Alan R. Liss, New York, pp. 205–223.Google Scholar
  74. 74.
    Bennett, A., Charlier, E.M., McDonald, A.M., et al. (1977). Prostaglandins and breast cancer. Lancet 2:624.PubMedCrossRefGoogle Scholar
  75. 75.
    Wynder, E.L., Rose, D.P. and Cohen, L.A. (1986) Diet and breast cancer in causation and therapy. Cancer 58:1804–1813.PubMedCrossRefGoogle Scholar
  76. 76.
    Hirayama, T. (1978) Epidemiology of breast cancer with special reference to the role of diet. Prev. Med. 7:173–195.PubMedCrossRefGoogle Scholar
  77. 77.
    Willett, W.C., Stampfer, M.J., Colditz, G.X., et al. (1987) Dietary fat and the risk of breast cancer. New Engl. J. Med. 316:22–28.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1989

Authors and Affiliations

  • O. J. Plescia
    • 1
  • J. Brown
    • 1
  • D. Lombardi
    • 2
  • L. Lenti
    • 2
  • S. Racis
    • 1
  • G. M. Pontieri
    • 2
  1. 1.Waksraan Institute of Microbiologyl Rutgers-The State University of New JerseyNew BrunswickUSA
  2. 2.Universita degli Studi La SapienzaRomeItaly

Personalised recommendations